• Search
  • Advanced Search

Search

  • HOME
  • Search
Original Article
Neonatology (Perinatology)
Neuroprotective effects of erythropoietin against hypoxic injury via modulation of the mitogen-activated protein kinase pathway and apoptosis
Ji Eun Jeong, Jae Hyun Park, Chun Soo Kim, Sang Lak Lee, Hai Lee Chung, Woo Taek Kim, Eun Joo Lee
Clin Exp Pediatr. 2017;60(6):181-188.   Published online June 22, 2017
Purpose

Hypoxic-ischemic encephalopathy is a significant cause of neonatal morbidity and mortality. Erythropoietin (EPO) is emerging as a therapeutic candidate for neuroprotection. Therefore, this study was designed to determine the neuroprotective role of recombinant human EPO (rHuEPO) and the possible mechanisms by which mitogen-activated protein kinase (MAPK) signaling pathway including extracellular signal-regulated kinase (ERK1/2), JNK, and p38 MAPK is modulated in...

Case Report
Nephrology (Genitourinary)
Recombinant Human Erythropoietin Therapy for a Jehovah's Witness Child With Severe Anemia due to Hemolytic-Uremic Syndrome
Da Eun Woo, Jae Min Lee, Yu Kyung Kim, Yong Hoon Park
Clin Exp Pediatr. 2016;59(2):100-103.   Published online February 29, 2016

Patients with hemolytic-uremic syndrome (HUS) can rapidly develop profound anemia as the disease progresses, as a consequence of red blood cell (RBC) hemolysis and inadequate erythropoietin synthesis. Therefore, RBC transfusion should be considered in HUS patients with severe anemia to avoid cardiac or pulmonary complications. Most patients who are Jehovah's Witnesses refuse blood transfusion, even in the face of life-threatening...

Original Article
The neuroprotective effect of recombinant human erythropoietin via an antiapoptotic mechanism on hypoxic-ischemic brain injury in neonatal rats
Moon Sun Kim, Yoo Kyung Seo, Hye Jin Park, Kye Hyang Lee, Kyung Hoon Lee, Eun Jin Choi, Jin Kyung Kim, Hai Lee Chung, Woo Taek Kim
Clin Exp Pediatr. 2010;53(10):898-908.   Published online October 31, 2010
Purpose

The neuroprotective effects of erythropoietin (EPO) have been recently shown in many animal models of brain injury, including hypoxic-ischemic (HI) encephalopathy, trauma, and excitotoxicity; however, limited data are available for such effects during the neonatal periods. Therefore, we investigated whether recombinant human EPO (rHuEPO) can protect against perinatal HI brain injury via an antiapoptotic mechanism.

Methods

The left carotid artery was ligated...

The effect of erythropoietin in neonatal rat model of hypoxic-ischemic brain injury
Heng-Mi Kim, Byung-Ho Choe, Soon-Hak Kwon, Yoon-Kyung Sohn
Clin Exp Pediatr. 2009;52(1):105-110.   Published online January 15, 2009
Purpose : Perinatal asphyxia is an important cause of neonatal mortality and subsequent lifelong neurodevelopmental handicaps. Although many treatment strategies have been tested, there is currently no clinically effective treatment to prevent or reduce the harmful effects of hypoxia and ischemia in humans. Erythropoietin (Epo) has been shown to exert neuroprotective effects in various brain injury models although the exact...
Erythropoietin Levels in Premature Infants Following Prolonged Treatment with Theophylline
Kug Hwan Kim, Eun Seok Yang, Sang Kee Park
Clin Exp Pediatr. 1997;40(9):1227-1231.   Published online September 15, 1997
Purpose : Theophylline, an adenosine antagonist commonly used in premature infants to treat apnea, has been shown to decrease erythropoietin levels in adults. We studied the effect of theophylline on serum erythropoietin levels in premature infants with apnea. Methods : Subject were 12 premature infants with apnea who were admitted to the NICU, Chosun University Hospital. The first dose of theophylline was 5mg/kg, given...
Prophylactic Treatment of Anemia of Prematurity with Recombinant Human Erythropoietin and High Doses of Iron
Young Ho Lee, Ahn Hong Choi, Soon Yong Lee, Jeong Sook Park, Bong Keun Choi, Hyoung Shim Chang
Clin Exp Pediatr. 1997;40(3):361-367.   Published online March 15, 1997
Purpose : We conducted randomized study to determine whether high doses(6mg/kg/ day) of iron would exert a more supplemental effect than low doses(3mg/kg/day), and which regimen of recombinant human erythropoietin(rHuEPO) and iron would be more beneficial in the prophylactic treatment of anemia of prematurity. Methods : We randomly assigned 38 sick premature infants who were more likely than symptom-free premature infants requiring erythrocyte transfusions for...
Effect of Recombinant Human Erythropoietin on the Anemia of Premature Infants
Young Ah Lee, Ki Soo Kim, Young Seo Park, Hyung Nam Moon, Chang Yee Hong
Clin Exp Pediatr. 1996;39(5):631-640.   Published online May 15, 1996
Purpose : To determine whether the prophylactic treatment with recombinant human erythropoietin(rHuEPO) for the anemia of prematurity would reduce the need for blood transfusions. Methods : We randomly assigned 17 premature infants to therHuEPO group and the control group. For the rHuEPO group (n=9, birth weight=1210¡¾156 g, gestational age=31.7¡¾1.9wk), rHuEPO (400U/kg) was given three times a week for 4 weeks, plus iron (8 mg/kg/day) and vitamin...
Evaluation of the Serum Erythropoietin Levels in Neonates
Soo Young Kweon, Gyoung Hee Kim
Clin Exp Pediatr. 1993;36(1):67-72.   Published online January 15, 1993
Erythropoietin is the major hormonal regulator of erythropoiesis. It is controlled by many factors induct=ing hypoxia in tissue. The serum erythropoietin levels of neonates have shown gradual decrease untill 1 month of age. Which they are reactivated in the period of pysiologic anemia. This change is exaggerated if the neonates are born prematurely, and the levels of erythropoietin respond to...